论文信息 - Long‐term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies - 字舞流文

Long‐term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

M. Dimopoulos | E. Kastritis | M. Gavriatopoulou | E. Terpos | M. Roussou | A. Tasidou | A. Ntalianis | C. Pamboucas | S. Toumanidis | M. Migkou | E. Psimenou | E. Kaldara | Despina Kalapanida | Savvas T. Toumanidis